JP2012519707A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519707A5
JP2012519707A5 JP2011553146A JP2011553146A JP2012519707A5 JP 2012519707 A5 JP2012519707 A5 JP 2012519707A5 JP 2011553146 A JP2011553146 A JP 2011553146A JP 2011553146 A JP2011553146 A JP 2011553146A JP 2012519707 A5 JP2012519707 A5 JP 2012519707A5
Authority
JP
Japan
Prior art keywords
epha3
antibody
cells
cell
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011553146A
Other languages
English (en)
Japanese (ja)
Other versions
JP5876728B2 (ja
JP2012519707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/026413 external-priority patent/WO2010102244A1/en
Publication of JP2012519707A publication Critical patent/JP2012519707A/ja
Publication of JP2012519707A5 publication Critical patent/JP2012519707A5/ja
Application granted granted Critical
Publication of JP5876728B2 publication Critical patent/JP5876728B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011553146A 2009-03-06 2010-03-05 ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法 Expired - Fee Related JP5876728B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15828509P 2009-03-06 2009-03-06
US61/158,285 2009-03-06
US16813009P 2009-04-09 2009-04-09
US61/168,130 2009-04-09
PCT/US2010/026413 WO2010102244A1 (en) 2009-03-06 2010-03-05 Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015122537A Division JP2015231994A (ja) 2009-03-06 2015-06-18 ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2012519707A JP2012519707A (ja) 2012-08-30
JP2012519707A5 true JP2012519707A5 (cg-RX-API-DMAC10.html) 2013-04-18
JP5876728B2 JP5876728B2 (ja) 2016-03-02

Family

ID=42370943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011553146A Expired - Fee Related JP5876728B2 (ja) 2009-03-06 2010-03-05 ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法
JP2015122537A Pending JP2015231994A (ja) 2009-03-06 2015-06-18 ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015122537A Pending JP2015231994A (ja) 2009-03-06 2015-06-18 ＥｐｈＡ３に対する抗体を用いた、白血病および慢性骨髄増殖性疾患の治療方法

Country Status (9)

Country Link
US (3) US8834870B2 (cg-RX-API-DMAC10.html)
EP (1) EP2403879A1 (cg-RX-API-DMAC10.html)
JP (2) JP5876728B2 (cg-RX-API-DMAC10.html)
CN (1) CN102405237A (cg-RX-API-DMAC10.html)
AU (1) AU2010221159B2 (cg-RX-API-DMAC10.html)
CA (1) CA2753995A1 (cg-RX-API-DMAC10.html)
EA (1) EA201101241A1 (cg-RX-API-DMAC10.html)
NZ (1) NZ594950A (cg-RX-API-DMAC10.html)
WO (1) WO2010102244A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
AU2010313621C1 (en) 2009-10-14 2015-11-26 Humanigen, Inc. Antibodies to EphA3
US11536713B2 (en) 2009-12-25 2022-12-27 Chugai Seiyaku Kabushiki Kaisha Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
SG189302A1 (en) 2010-10-06 2013-05-31 Pharmalogicals Res Pte Ltd Cancer stem cell population and method for production thereof
GB201021623D0 (en) * 2010-12-21 2011-02-02 Isis Innovation Detection of acute myeloid leukaemia
AU2012295334A1 (en) * 2011-08-12 2013-05-02 Kalobios Pharmaceuticals, Inc. Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
EP3603671A3 (en) * 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
EP3572425A1 (en) * 2013-12-17 2019-11-27 AIMM Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
US20260055195A1 (en) * 2019-10-09 2026-02-26 The Council Of The Queensland Institute Of Medical Research Targeting epha3 and uses thereof
CN117192121A (zh) * 2023-08-30 2023-12-08 北京大学人民医院 用于mds和/或aml微小残留病检测的抗体组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE278019T1 (de) 1991-06-21 2004-10-15 Inst Medical W & E Hall Neuartige rezeptor-typ tyrosinkinase und deren verwendung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1094110A1 (en) 1999-10-21 2001-04-25 Leadd B.V. Apoptosis inducing proteinaceous substance
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
US7981843B2 (en) 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EP3199180B1 (en) * 2007-03-08 2022-01-05 Humanigen, Inc. Epha3 antibodies for the treatment of solid tumors

Similar Documents

Publication Publication Date Title
CO6260105A2 (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
NZ740686A (en) Therapeutic cd47 antibodies
EA201070596A1 (ru) Гуманизированные антитела против tl1a
MX2017002875A (es) Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1.
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
JP2014240385A5 (cg-RX-API-DMAC10.html)
JP2017535257A5 (cg-RX-API-DMAC10.html)
JP2018534933A5 (cg-RX-API-DMAC10.html)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2015520758A5 (cg-RX-API-DMAC10.html)
JP2017507652A5 (cg-RX-API-DMAC10.html)
NZ739750A (en) Anti-tigit antibodies and methods of use
JP2013227339A5 (cg-RX-API-DMAC10.html)
JP2013198490A5 (cg-RX-API-DMAC10.html)
EA201791876A1 (ru) Моноклональные антитела к прогастрину и их применение
NO20091712L (no) Nye anti-CD38-antistoffer for behandling av cancer
JP2013538057A5 (cg-RX-API-DMAC10.html)
RU2016101109A (ru) Медицинское применение агонистов cd38
JP2008537778A5 (cg-RX-API-DMAC10.html)
WO2010102276A3 (en) Humanized anti-cd19 antibody formulations
JP2013542194A5 (cg-RX-API-DMAC10.html)
JP2008507530A5 (cg-RX-API-DMAC10.html)
RS59605B1 (sr) Kombinacija anti-cd19 antitela i inhibitora brutonove tirozin kinaze i njene upotrebe
JP2015530399A5 (cg-RX-API-DMAC10.html)
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target